Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mitsubishi Corporation

https://www.mhi-global.com

Latest From Mitsubishi Corporation

Japan's Price Cuts Slated For April Bring Old, New Blues For Industry

Next month’s regular reimbursement price cut in Japan includes some large reductions for big-selling drugs, while one new rule has been applied for the first time.

Japan Policy

Asahi Paying $1.3bn For One-Product Veloxis

Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.

M & A Business Strategies

Supreme Court Refuses Inter Partes Review

Standards of evidence for obviousness used in US inter partes patent reviews will not be reviewed by the US Supreme Court. Nor will the court consider whether the Federal Circuit can confirm inter partes decisions without issuing an opinion.

Intellectual Property Legal Issues

Top US Court Is Asked To Review Inter Partes Reviews

Standards for determining obviousness via inter partes patent reviews, as well as procedures for affirming such determinations on appeal, must be reviewed by the US Supreme Court, two originators argue in their dispute with Akorn over Durezol difluprednate eye drops.

Intellectual Property Legal Issues
See All

Company Information

  • Industry
  • Distributors
  • Diversified
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Japan Medicalnext Co., Ltd.
    • MC Healthcare, Inc.
UsernamePublicRestriction

Register